BioCentury
ARTICLE | Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

June 4, 2018 10:10 PM UTC

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a TCR cell therapy targeting E7 transforming protein (HPV-16; HpV16gp2) led to three partial responses and two cases of stable disease.

Kite said the data, which were presented Monday at the American Society of Clinical Oncology (ASCO) meeting in Chicago, support development of the company's TCR candidate KITE-439 in the indication. The company plans to submit an IND by year end for KITE-439 to treat HPV-16 E7 solid tumors...